{
    "clinical_study": {
        "@rank": "55206", 
        "arm_group": [
            {
                "arm_group_label": "Ortho-Cyclen", 
                "arm_group_type": "Experimental", 
                "description": "Ortho-Cyclen (35 microgram (mcg) ethinyl estradiol and 250 mcg norgestimate) administered orally, once daily (QD), for 28 days (lead-in period).  Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) in one of two treatment periods."
            }, 
            {
                "arm_group_label": "Ortho-Cyclen  + Evacetrapib", 
                "arm_group_type": "Experimental", 
                "description": "Ortho-Cyclen administered orally, QD, for 28 days (lead-in period).  Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) and 130 mg evacetrapib orally, QD, for 21 days (Days 1 to 21) in one of two treatment periods."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of evacetrapib on oral contraceptives\n      (Ortho-Cyclen\u00ae) when given to healthy female participants. The amount of female hormones\n      found in the blood will be measured and compared when  taken alone and when taken with\n      evaceptrapib.  Each woman will participate in two study periods.  Information about any side\n      effects that may occur will also be collected."
        }, 
        "brief_title": "A Study of Evacetrapib in Healthy Female Participants", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are pre-menopausal females, and who are healthy as determined by medical history and\n             physical examination\n\n          -  Have a body mass index of 18 to 30 kilograms per square meter (kg/m^2)\n\n        Exclusion Criteria:\n\n          -  Have known allergies to evacetrapib and Ortho-Cyclen (ethinyl estradiol and\n             norgestimate), related compounds or any components of the formulation\n\n          -  Have a clinically significant abnormality in the 12-lead electrocardiogram (ECG)\n             that, in the opinion of the investigator, increases the risks associated with\n             participating in the study\n\n          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug\n             screening\n\n          -  Have taken injectable contraceptives within 12 months prior to the first dose of the\n             lead-in period or topical controlled delivery contraceptives (patch) for 3 months\n             prior to the first dose of the lead-in period\n\n          -  Use of any tobacco- or nicotine-containing products within 6 months prior to the\n             lead-in phase and during the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746732", 
            "org_study_id": "14617", 
            "secondary_id": "I1V-MC-EIAP"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ortho-Cyclen", 
                    "Ortho-Cyclen  + Evacetrapib"
                ], 
                "description": "Oral administration", 
                "intervention_name": "Ortho-Cyclen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ortho-Cyclen  + Evacetrapib", 
                "description": "Oral administration", 
                "intervention_name": "Evacetrapib", 
                "intervention_type": "Drug", 
                "other_name": "LY2484595"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptives, Oral", 
                "Norgestimate, ethinyl estradiol drug combination", 
                "Moxifloxacin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of Norgestimate/Ethinyl Estradiol", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Post-dose on Day 21"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUC\u03c4) of Norgestimate/Ethinyl Estradiol", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Post-dose on Day 21"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Minimum Observed Drug Concentration (Cmin) of Norgestimate/Ethinyl Estradiol", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Post-dose on Day 21"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Norgestimate/Ethinyl Estradiol", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Post-dose on Day 21"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746732"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}